Suppr超能文献

加速超分割放疗治疗新诊断胶质母细胞瘤的老年或体弱患者:4 项前瞻性试验患者水平数据的汇总分析。

Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.

机构信息

Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Ohio State University School of Medicine, Columbus, Ohio.

出版信息

Cancer. 2022 Jun 15;128(12):2367-2374. doi: 10.1002/cncr.34192. Epub 2022 Mar 22.

Abstract

BACKGROUND

The standard of care for elderly or frail patients with glioblastoma (GBM) is 40 Gy in 15 fractions of radiotherapy. However, this regimen has a lower biological effective dose (BED) compared with the Stupp regimen of 60 Gy in 30 fractions. It is hypothesized that accelerated hypofractionated radiation of 52.5 Gy in 15 fractions (BED equivalent to Stupp) is safe and efficacious.

METHODS

Elderly or frail patients with GBM treated with 52.5 Gy in 15 fractions were pooled from 3 phase 1/2 studies and a prospective observational study. Overall survival (OS) and progression-free survival (PFS) were defined time elapsing between surgery/biopsy and death from any cause or progression of disease.

RESULTS

Sixty-two newly diagnosed patients were eligible for this pooled analysis of individual patient data. The majority (66%) had a Karnofsky performance status (KPS) score <70. The median age was 73 years. The median OS and PFS were 10.3 and 6.9 months, respectively. Patients with KPS scores ≥70 and <70 had a median OS of 15.3 and 9.5 months, respectively. Concurrent chemotherapy was an independent prognostic factor for improved PFS and OS. Grade 3 neurologic toxicity was seen in 2 patients (3.2%). There was no grade 4/5 toxicity.

CONCLUSIONS

This is the only analysis of elderly/frail patients with GBM prospectively treated with a hypofractionated radiation regimen that is isoeffective to the Stupp regimen. Treatment was well tolerated and demonstrated excellent OS and PFS compared with historical studies. This regimen gives the elderly/frail population an alternative to regimens with a lower BED. Randomized trials are needed to validate these results.

摘要

背景

对于老年或体弱的胶质母细胞瘤(GBM)患者,标准治疗方案是放疗 40Gy,共 15 次分割。然而,与 60Gy,共 30 次分割的 Stupp 方案相比,这种方案的生物有效剂量(BED)较低。假设 52.5Gy,共 15 次分割的加速亚分割放疗(BED 等效于 Stupp)是安全有效的。

方法

从 3 项 1/2 期研究和一项前瞻性观察研究中汇集了接受 52.5Gy,共 15 次分割治疗的老年或体弱的 GBM 患者。总生存期(OS)和无进展生存期(PFS)定义为手术/活检后至任何原因死亡或疾病进展的时间。

结果

62 例新诊断的患者符合本研究的纳入标准。大多数患者(66%)的 Karnofsky 表现状态(KPS)评分<70。中位年龄为 73 岁。中位 OS 和 PFS 分别为 10.3 个月和 6.9 个月。KPS 评分≥70 和<70 的患者中位 OS 分别为 15.3 个月和 9.5 个月。同期化疗是改善 PFS 和 OS 的独立预后因素。2 例患者(3.2%)出现 3 级神经毒性。无 4/5 级毒性。

结论

这是唯一一项前瞻性治疗老年/体弱的 GBM 患者的亚分割放疗方案的分析,与 Stupp 方案等效。该治疗方案耐受性良好,与历史研究相比,OS 和 PFS 表现出色。与低 BED 方案相比,该方案为老年/体弱人群提供了一种替代方案。需要进行随机试验来验证这些结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验